Liberia

Liberia

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
10.03 (8.18 - 11.83) 2019 Modelled IHME
10.5 (8.71 - 12.33) 2018 Modelled IHME
10.79 (8.87 - 12.65) 2017 Modelled IHME
10.89 (8.91 - 12.76) 2016 Modelled IHME
10.98 (8.82 - 13.20) 2015 Modelled IHME
11.24 (9.06 - 13.42) 2014 Modelled IHME
11.66 (9.39 - 13.86) 2013 Modelled IHME
12.15 (9.80 - 14.47) 2012 Modelled IHME
12.62 (10.13 - 15.02) 2011 Modelled IHME
12.97 (10.31 - 15.48) 2010 Modelled IHME
13.22 (10.39 - 15.54) 2009 Modelled IHME
13.44 (10.42 - 15.78) 2008 Modelled IHME
13.64 (10.45 - 16) 2007 Modelled IHME
13.81 (10.50 - 16.27) 2006 Modelled IHME
13.98 (10.54 - 16.62) 2005 Modelled IHME
14.14 (10.70 - 16.68) 2004 Modelled IHME
14.32 (10.83 - 16.87) 2003 Modelled IHME
14.47 (10.97 - 17.15) 2002 Modelled IHME
14.6 (11.12 - 17.42) 2001 Modelled IHME
14.67 (11.21 - 17.69) 2000 Modelled IHME
14.71 (11.42 - 17.49) 1999 Modelled IHME
14.76 (11.61 - 17.47) 1998 Modelled IHME
14.79 (11.82 - 17.41) 1997 Modelled IHME
14.82 (11.90 - 17.39) 1996 Modelled IHME
14.83 (11.86 - 17.56) 1995 Modelled IHME
14.8 (11.87 - 17.31) 1994 Modelled IHME
14.71 (11.93 - 17.20) 1993 Modelled IHME
14.59 (11.95 - 17.05) 1992 Modelled IHME
14.43 (11.84 - 17.01) 1991 Modelled IHME
14.26 (11.72 - 16.89) 1990 Modelled IHME
14.9 (11.94 - 18.39) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
2.2 (1.55 - 2.80) 2019 Modelled IHME
2.22 (1.57 - 2.82) 2018 Modelled IHME
2.26 (1.59 - 2.90) 2017 Modelled IHME
2.82 (2 - 3.68) 2016 Modelled IHME
3.52 (2.46 - 4.70) 2015 Modelled IHME
3.77 (2.67 - 4.97) 2014 Modelled IHME
3.93 (2.78 - 5.10) 2013 Modelled IHME
4.06 (2.85 - 5.23) 2012 Modelled IHME
4.23 (2.96 - 5.47) 2011 Modelled IHME
4.5 (3.13 - 5.85) 2010 Modelled IHME
5.4 (3.71 - 6.95) 2009 Modelled IHME
7.09 (4.79 - 9.07) 2008 Modelled IHME
9.02 (5.97 - 11.66) 2007 Modelled IHME
10.67 (6.95 - 13.92) 2006 Modelled IHME
11.51 (7.53 - 15.02) 2005 Modelled IHME
11.74 (7.78 - 15.14) 2004 Modelled IHME
11.92 (7.97 - 15.28) 2003 Modelled IHME
12.06 (8.10 - 15.44) 2002 Modelled IHME
12.16 (8.15 - 15.54) 2001 Modelled IHME
12.22 (8.20 - 15.70) 2000 Modelled IHME
12.27 (8.33 - 15.52) 1999 Modelled IHME
12.31 (8.41 - 15.61) 1998 Modelled IHME
12.35 (8.48 - 15.82) 1997 Modelled IHME
12.38 (8.48 - 15.92) 1996 Modelled IHME
12.39 (8.47 - 15.95) 1995 Modelled IHME
12.35 (8.61 - 15.70) 1994 Modelled IHME
12.26 (8.66 - 15.48) 1993 Modelled IHME
12.12 (8.61 - 15.14) 1992 Modelled IHME
11.95 (8.61 - 14.81) 1991 Modelled IHME
11.75 (8.65 - 14.72) 1990 Modelled IHME
7.75 (5.56 - 10.44) 2015 Modelled WHO
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
50 (42 - 59) 2019 Modelled IHME
51 (43 - 60) 2018 Modelled IHME
51 (43 - 60) 2017 Modelled IHME
51 (43 - 60) 2016 Modelled IHME
51 (43 - 59) 2015 Modelled IHME
51 (43 - 59) 2014 Modelled IHME
51 (42 - 59) 2013 Modelled IHME
50 (42 - 59) 2012 Modelled IHME
50 (42 - 59) 2011 Modelled IHME
50 (42 - 59) 2010 Modelled IHME
50 (42 - 58) 2009 Modelled IHME
50 (42 - 58) 2008 Modelled IHME
50 (42 - 59) 2007 Modelled IHME
50 (41 - 59) 2006 Modelled IHME
50 (41 - 59) 2005 Modelled IHME
50 (41 - 59) 2004 Modelled IHME
50 (41 - 59) 2003 Modelled IHME
50 (41 - 59) 2002 Modelled IHME
50 (41 - 59) 2001 Modelled IHME
50 (41 - 59) 2000 Modelled IHME
50 (41 - 59) 1999 Modelled IHME
50 (42 - 59) 1998 Modelled IHME
50 (42 - 59) 1997 Modelled IHME
50 (42 - 60) 1996 Modelled IHME
50 (41 - 59) 1995 Modelled IHME
50 (41 - 60) 1994 Modelled IHME
50 (41 - 59) 1993 Modelled IHME
50 (41 - 59) 1992 Modelled IHME
50 (41 - 60) 1991 Modelled IHME
50 (41 - 60) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
84 2018 Survey/reported WHO/UNICEF
86 2017 Survey/reported WHO/UNICEF
79 2016 Survey/reported WHO/UNICEF
52 2015 Survey/reported WHO/UNICEF
50 2014 Survey/reported WHO/UNICEF
76 2013 Survey/reported WHO/UNICEF
80 2012 Survey/reported WHO/UNICEF
77 2011 Survey/reported WHO/UNICEF
47 2010 Survey/reported WHO/UNICEF
64 2009 Survey/reported WHO/UNICEF
64 2008 Survey/reported WHO/UNICEF
Showing out of
Show more

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
0 (0 - 0) 2016 Survey/reported Harm Reduction International, 2016

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
No
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
2.56 (2.06 - 3.22) 2019 Modelled IHME
2.55 (2.04 - 3.19) 2018 Modelled IHME
2.54 (2.03 - 3.17) 2017 Modelled IHME
2.54 (2.03 - 3.18) 2016 Modelled IHME
2.54 (2.02 - 3.18) 2015 Modelled IHME
2.55 (2.03 - 3.21) 2014 Modelled IHME
2.57 (2.07 - 3.23) 2013 Modelled IHME
2.6 (2.10 - 3.27) 2012 Modelled IHME
2.64 (2.12 - 3.30) 2011 Modelled IHME
2.67 (2.15 - 3.35) 2010 Modelled IHME
2.7 (2.17 - 3.39) 2009 Modelled IHME
2.73 (2.20 - 3.44) 2008 Modelled IHME
2.76 (2.23 - 3.47) 2007 Modelled IHME
2.79 (2.25 - 3.50) 2006 Modelled IHME
2.83 (2.27 - 3.55) 2005 Modelled IHME
2.86 (2.31 - 3.59) 2004 Modelled IHME
2.91 (2.34 - 3.64) 2003 Modelled IHME
2.95 (2.38 - 3.70) 2002 Modelled IHME
2.99 (2.41 - 3.76) 2001 Modelled IHME
3.03 (2.45 - 3.82) 2000 Modelled IHME
3.07 (2.47 - 3.86) 1999 Modelled IHME
3.11 (2.51 - 3.91) 1998 Modelled IHME
3.15 (2.55 - 3.95) 1997 Modelled IHME
3.17 (2.57 - 3.97) 1996 Modelled IHME
3.18 (2.59 - 3.99) 1995 Modelled IHME
3.18 (2.59 - 3.99) 1994 Modelled IHME
3.18 (2.58 - 3.99) 1993 Modelled IHME
3.18 (2.58 - 3.98) 1992 Modelled IHME
3.17 (2.56 - 3.96) 1991 Modelled IHME
3.15 (2.53 - 3.94) 1990 Modelled IHME
Showing out of
Show more

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
17 (12 - 23) 2019 Modelled IHME
17 (12 - 23) 2018 Modelled IHME
17 (11 - 23) 2017 Modelled IHME
17 (11 - 23) 2016 Modelled IHME
17 (12 - 23) 2015 Modelled IHME
17 (12 - 23) 2014 Modelled IHME
17 (12 - 23) 2013 Modelled IHME
17 (12 - 23) 2012 Modelled IHME
17 (12 - 23) 2011 Modelled IHME
18 (12 - 24) 2010 Modelled IHME
18 (12 - 24) 2009 Modelled IHME
18 (13 - 25) 2008 Modelled IHME
18 (12 - 24) 2007 Modelled IHME
18 (12 - 25) 2006 Modelled IHME
18 (12 - 25) 2005 Modelled IHME
18 (12 - 25) 2004 Modelled IHME
19 (13 - 25) 2003 Modelled IHME
19 (13 - 25) 2002 Modelled IHME
19 (13 - 25) 2001 Modelled IHME
19 (13 - 25) 2000 Modelled IHME
18 (12 - 25) 1999 Modelled IHME
18 (12 - 25) 1998 Modelled IHME
18 (12 - 25) 1997 Modelled IHME
18 (12 - 25) 1996 Modelled IHME
18 (12 - 25) 1995 Modelled IHME
18 (12 - 25) 1994 Modelled IHME
18 (12 - 25) 1993 Modelled IHME
18 (12 - 25) 1992 Modelled IHME
17 (12 - 24) 1991 Modelled IHME
17 (12 - 24) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 (0 - 0) 2016 Survey/reported Harm Reduction International, 2016

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
No
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
10.03 (%)
2019
(8.18 - 11.83(%))
IHME
HCV (RNA/cAg+)
2.56 (%)
2019
(2.06 - 3.22(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
519
2019
(365 - 733)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
77
2019
(53 - 111)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
2.20 (%)
2019, latest modelled
(1.55 - 2.80(%))
IHME

Prevalence PWID

No data available

Birth dose vaccination coverage (national)

Survey/surveillance

No data available

No. of syringes/PWID/year

Survey/surveillance

HCV
0
2016
(0 - 0)
Harm Reduction International, 2016
Eligible for HBV generic medicines
Eligible for HCV generic medicines